Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Account Payables (2018 - 2025)

10x Genomics (TXG) has disclosed Change in Account Payables for 8 consecutive years, with -$5.4 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 59.56% to -$5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2025, up 36.61% year-over-year, with the annual reading at -$2.1 million for FY2025, 36.61% up from the prior year.
  • Change in Account Payables hit -$5.4 million in Q4 2025 for 10x Genomics, down from -$196000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $10.9 million in Q1 2021 to a low of -$13.4 million in Q4 2024.
  • Historically, Change in Account Payables has averaged $272250.0 across 5 years, with a median of -$210000.0 in 2022.
  • Biggest five-year swings in Change in Account Payables: surged 1766.92% in 2021 and later crashed 1331.25% in 2023.
  • Year by year, Change in Account Payables stood at -$1.1 million in 2021, then soared by 79.77% to -$224000.0 in 2022, then plummeted by 1331.25% to -$3.2 million in 2023, then crashed by 317.9% to -$13.4 million in 2024, then surged by 59.56% to -$5.4 million in 2025.
  • Business Quant data shows Change in Account Payables for TXG at -$5.4 million in Q4 2025, -$196000.0 in Q3 2025, and $6.0 million in Q2 2025.